Inrebic (fedratinib) is a small molecule pharmaceutical. Fedratinib was first approved as Inrebic on 2019-08-16. It is used to treat primary myelofibrosis in the USA. It has been approved in Europe to treat myeloproliferative disorders and primary myelofibrosis. The pharmaceutical is active against tyrosine-protein kinase JAK2. In addition, it is known to target tyrosine-protein kinase JAK1, tyrosine-protein kinase JAK3, bromodomain-containing protein 4, and non-receptor tyrosine-protein kinase TYK2. Inrebic's patents are valid until 2032-06-04 (FDA).
|Indication||myeloproliferative disorders, primary myelofibrosis|
|Drug Class||Tyrosine kinase inhibitors|